BackTable / Tumor Board / Podcast / Episode #30

NMIBC Tumor Board: Nuances in Management

with Dr. Mark Tyson and Dr. Sarah Psutka

When standard therapy fails, it does not have to be the end of the road for high-risk bladder cancer patients. Modern treatments, biomarkers, and clinical studies have opened up new avenues for treating recurrent non-muscle invasive bladder cancer (NMIBC). The penultimate episode of the 2025 NMIBC Creator Weekend™ series features urologic oncologists Dr. Vignesh Packiam, Dr. Mark Tyson, and Dr. Sarah Psutka discussing how they navigate complex bladder cancer scenarios.

This podcast is supported by:

Ferring Pharmaceuticals

Be part of the conversation. Put your sponsored messaging on this episode. Learn how.

NMIBC Tumor Board: Nuances in Management with Dr. Mark Tyson and Dr. Sarah Psutka on the BackTable Tumor Board Podcast

Ep 30 NMIBC Tumor Board: Nuances in Management with Dr. Mark Tyson and Dr. Sarah Psutka

00:00 / 01:04

BackTable, LLC (Producer). (2025, October 7). Ep. 30 – NMIBC Tumor Board: Nuances in Management [Audio podcast]. Retrieved from https://www.backtable.com

Stay Up To Date

Follow:

Subscribe:

Podcast Contributors

Dr. Vignesh Packiam

Dr. Vignesh Packiam is an associate professor of urologic oncology at Rutgers Cancer Institute of New Jersey.

Dr. Sarah Psutka

Dr. Sarah Psutka is a urologic oncologist and associate professor at University of Washington in Seattle.

Dr. Mark Tyson

Dr. Mark Tyson is a urologic oncologist and professor of urology with Mayo Clinic in Scottsdale, Arizona.

Synopsis

The doctors share treatment strategies, staging processes, and post-therapy patient management techniques. They address recurrent disease, approaches to different stages of cancer, the role of biomarkers in determining treatment paths, and considerations for both high-risk and intermediate-risk patients. Additionally, the episode touches on new treatments, clinical trials, and patient quality of life post-treatment.

Timestamps

00:00 - Introduction
02:08 - Case Study: Initial Patient Assessment
04:59 - Surgical Considerations and Techniques
10:22 - Managing Bladder Cancer Recurrence
11:15 - Treatment Options and Clinical Trials
15:12 - Advanced Treatment Strategies
28:14 - Closing Remarks and Credits

Resources

VISTA Trial https://abstracts.mirrorsmed.org/abstracts/vista-phase-3-trial-vicinium-epcam-targeted-pseudomonas-exotoxin-bcg-unresponsive-non

BRIDGE Trial
https://pmc.ncbi.nlm.nih.gov/articles/PMC10515442/

CORE-008 Trial
https://www.sciencedirect.com/science/article/abs/pii/S1078143924010147

GAIN Trial
https://pmc.ncbi.nlm.nih.gov/articles/PMC10176900/

The Materials available on BackTable are for informational and educational purposes only and are not a substitute for the professional judgment of a healthcare professional in diagnosing and treating patients. The opinions expressed by participants of the BackTable Podcast belong solely to the participants, and do not necessarily reflect the views of BackTable.

Up Next

NSCLC Tumor Board Discussion: Considerations for Oligometastatic Disease with Dr. Karen Reckamp, Dr. Scott Atay, Dr. Scott Oh, Dr. Alan Lee and Dr. Scott Genshaft on the BackTable Tumor Board Podcast

Keynote-689: Implementation & Multidisciplinary Care for Immunotherapy in Head & Neck Cancer with Dr. Adam Luginbuhl, Dr. Jennifer Johnson, Dr. Mihir Patel and Dr. Siddharth Sheth on the BackTable Tumor Board Podcast

Getting Started in Interventional Oncology: Tips for Starting Your Career with Dr. Sid Padia, Dr. Kevin Burns, Dr. Tyler Sandow and Dr. Venkatesh Krishnasamy on the BackTable Tumor Board Podcast

Complex HCC Patients & The "Grey Zone": What To Do When You Don’t Know What To Do with Dr. Adam Burgoyne, Dr. Zach Berman, Dr. Kirema Garcia-Reyes and Dr. Lingling Du on the BackTable Tumor Board Podcast

Articles

Topics

Get in touch!

We want to hear from you. Let us know if you’re interested in partnering with BackTable as a Podcast guest, a sponsor, or as a member of the BackTable Team.